Identifying and therapeutically targeting cancer cell liabilities is of utmost importance in order to improve the treatment of patients with malignancies of poor prognosis. The MYC family genes (MYC, MYCN and MYCL) are among the most deregulated proto-oncogenes in human cancer. Aberrant MYC expression is frequently associated with poor prognosis. Although many aspects of MYC-mediated tumour biology are well characterized, there are currently no effective means for targeting MYC in a specific manner that have been established for clinical use. This review first discusses the role of MYC in the pathogenesis of haematopoietic malignancies, and secondly summarizes how insight into MYC functions could be translated into therapeutic approaches. In particular, we will address the possibilities of taking advantage of MYC-induced cancer cell vulnerabilities that could be exploited in terms of synthetic lethal interactions.
MYC (also termed c-Myc; encoded by MYC) is a transcription factor containing a basic helix-loop-helix (bHLH) and a leucine zipper domain for DNA-binding and heterodimer formation with MYC associated factor X (MAX), respectively. The MYC family of transcription factors includes MYC, L-MYC and N-MYC with similar structure and function [reviewed in (Eilers & Eisenman, 2008; Meyer & Penn, 2008) ]. We will focus on MYC due to its well-established impact on initiation and progression of haematological malignancies. MYC received its name from oncogenic retroviruses integrating a virally encoded oncogene (v-myc) into chicken DNA, thereby causing leukaemia and sarcoma-like cancers (myelocytomatosis) (Sheiness & Bishop, 1979) . This discovery eventually lead to the identification of the human homologue MYC and its involvement in many human cancers, especially haematological neoplasms.
In physiological processes, MYC expression and stability is tightly regulated to limit its activity to the adequate biological context (Eilers & Eisenman, 2008; Meyer & Penn, 2008) . MYC deficiency by means of gene knock-out is lethal early during embryogenesis, emphasizing its fundamental role in organogenesis and developmental biology (Davis et al, 1993) .
In cancer, oncogenic activation of signal transduction results in a growth promoting change in transcription. When MYC levels are elevated by events leading to increased expression or stability, the growth promoting transcriptome is further enhanced (Lin et al, 2012) . By binding to E-boxes that are present throughout the genome but only accessible to MYC in open chromatin, MYC can recruit histone acetyltransferases (HATs) to other chromatin remodelling complexes to stimulate transcriptional elongation. Some E-boxes and genes are high affinity targets whereas other genes are low affinity and thus require high MYC levels to be bound and activated. MYC can also repress genes via interaction with factors such as ZBTB17 (also termed Miz-1) or by inducing MNT, which works as an anti-amplifier, or by simply inducing all genes in open chromatin so that everything else appears suppressed if not properly normalized (Nilsson et al, 2004; Wolf et al, 2015) .
In primarily MYC-driven cancers, the grossly elevated MYC levels (Sabo et al, 2014) can therefore lead to enhanced transcription of apoptosis pathways, including the activation of the CDKN2A-TP53 (Arf-p53) apoptotic pathway. Loss of apoptotic failsafe mechanism results in rapid onset of aggressive cancers as shown, for example, in mouse models of B-cell lymphoma (Eischen et al, 1999) .
MYC's prominent role as a pivotal oncoprotein makes it an attractive target for pharmacological inhibition. Indeed, a mouse model expressing a switchable dominant negative form of MYC, called OmoMyc has demonstrated that MYC can be inactivated in cancer cells without causing detrimental tissue homeostasis (Soucek et al, 2008) . However, the lack of hydrophobic pockets, unorganized tertiary structure and protein-protein interactions has made development of highly selective inhibitory molecules extremely difficult, and MYC is therefore often referred to as 'undruggable' (McKeown & Bradner, 2014) . These challenges led to the idea of targeting cellular processes selectively perturbed in cancer cells with high MYC levels, thereby conferring so called 'synthetic lethality' (Kaelin, 2005) . This approach is highly attractive due to sparing of non-cancer cells and thus reducing toxicity. Here, we discuss MYC's influence on, and significance in, haematological cancers and how MYCinduced liabilities could be targeted to develop novel therapeutic strategies.
Role of MYC in the pathobiology of haematological malignancies
MYC is an essential oncogene in haematological cancers. An overview of haematological malignancies with known MYC involvement and influence on disease course or clinical characteristics is provided in Table I .
B-cell malignancies
Burkitt lymphoma (BL) is the human disease in which MYC was initially discovered and found to play an essential role in initiation and progression. In the early 1980's, 3 translocations of the MYC gene on the long arm of chromosome 8 to the immunoglobulin heavy locus [IGH; t(8;14)(q24;q32)], the j light chain locus [IGK; t(2;8)(p11;q24)] and the k light chain locus [IGL; t(8;22)(q24;q11)] were found to be pathognomonic for BL (Dalla-Favera et al, 1982; Taub et al, 1982) . The fact that BL is presumably the fastest growing human cancer, with doubling times often less than 1-2 days, emphasizes the dramatic effect of aberrant MYC expression. Epstein-Barr virus (EBV) infection plays a role in endemic BL and EBV nuclear antigen 2 (EBNA2) is itself known to activate MYC and thereby increase B cell proliferation. The exact pathogenesis of BL is not known but probably involves an intricate balance between the growth promoting and antiapoptotic effects of EBV and the B-cell receptor (BCR) and how these are being amplified by MYC. Endemic BL also involves an immune escape (Durand-Panteix et al, 2012) . Despite the highly aggressive nature of BL, both endemic and sporadic BL have an excellent prognosis if treated appropriately with aggressive immuno-chemotherapy (Hoelzer et al, 2014) .
MYC translocations are present in 5-10% of diffuse large B cell lymphoma (DLBCL) cases and are associated with a worse prognosis and increased risk for relapse both systemically and within the central nervous system (Savage et al, 2009) . Concomitant translocations involving B-cell lymphoma 2 (BCL2) and/or B-cell lymphoma 6 (BCL6) [double-(DHL) or triple-hit lymphoma] are common in this subset of DLBCLs, contributing to adverse prognosis. Expression of MYC and BCL2 evaluated by immunohistochemistry [so called 'double-expressor' lymphomas (DEL)] also defines a subgroup with worse prognosis (Johnson et al, 2012) . Due to this prognostic significance, the new 2016 World Health Organization (WHO) classification of haematological malignancies introduced a new provisional lymphoma entity named 'high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 translocations' (Swerdlow et al, 2016) . Currently, there is no consensus if intensified chemotherapeutic regimens or high-dose chemotherapy with haematopoietic stem cell transplantation (HSCT) improves prognosis in DHL/DEL. Therefore, inclusion of this patient population into clinical trials testing intensified regimens or targeted substances is warranted. Recent work demonstrated that MYC augments BCR signalling events and that MYC overexpression confers resistance to the Bruton tyrosine kinase inhibitor ibrutinib in a MYC-induced lymphoma model. This implicates that targeting BCR signalling in MYC-driven lymphomas might be more challenging than anticipated and that regimens rationally combining inhibition of BCR with inhibition of potential resistance mechanisms might be beneficial (Moyo et al, 2017) .
MYC translocations can also be found in transformed or high-grade follicular lymphoma (FL) (Pasqualucci et al, 2014) , indicating a more aggressive phenotype with adverse prognosis, similar to the aforementioned DHL . However, in a recent study including high-and low grade FL, MYC breaks were also found in 6Á3% of low-grade FL, but the fraction of cells affected by this alteration was low compared to high-grade FL with MYC translocations (Leich et al, 2016) . These data reflect the complexity in the continuum of transformation of FL into a more aggressive disease, where the role of MYC activation is not fully understood.
Mantle cell lymphoma (MCL) is characterized by increased proliferation and cell cycle progression mediated by the t(11;14)(q13;q32) translocation leading to overexpression of CyclinD1 (CCND1). Further genetic perturbations altering proliferation, the DNA damage response (DDR), or apoptosis are frequently acquired leading to lymphoma progression. Case studies suggest a role of translocations involving MYC that are associated with adverse prognosis and aggressive behaviour (Nagy et al, 2003) . Apart from the known collaboration between CCND1 and MYC (Bodrug et al, 1994) , recent data suggests that in a subset of patients mutated Notch homologue 1 (NOTCH1) leads to MYC overexpression (Kridel et al, 2012) .
Post-transplant lymphoproliferative disorders (PTLD) are a group of diseases caused by immunosuppression after solid organ transplantation or, less frequently, HSCT. Most cases are associated with EBV-induced B-cell proliferation when T-cell surveillance is compromised by immunosuppression, but EBV negative cases also occur (Randhawa et al, 1992) . Apart from post-transplant BL, which also displays the characteristic t(8;14) translocation known from endemic and sporadic BL, MYC expression is also directly activated by EBVencoded EBNA2 (Kaiser et al, 1999) . Li et al (2014) Chronic lymphocytic leukaemia (CLL) most often displays an indolent course of disease without requiring treatment for years. Apart from well-established prognostic factors like del (17p), CD38 expression, ZAP70 expression and IGHV mutation status, MYC translocations have also been implicated to be present and associated with a more aggressive phenotype (Huh et al, 2008) . In transformed CLL (Richter syndrome), MYC alterations are present in 26Á2% of patients, suggesting that these alterations might drive transformation (Rossi et al, 2011) . Whole genome sequencing of 538 CLL patients also identified MYC as a central player in this disease (Landau et al, 2015) . NOTCH1, which can be mutated in CLL, has recently been shown to regulate MYC expression in CLL (Pozzo et al, 2017) and NOTCH1-MYC activation by the stromal niche induces metabolic changes associated with increased glucose dependence (Jitschin et al, 2015) .
B-prolymphocytic leukaemia (B-PLL) is a rare mature B-cell neoplasm occurring in the elderly, often associated with adverse prognosis and clinical and pathological features between CLL and MCL (van der Velden et al, 2014). A MYC amplification or t(8;14) translocation could be detected in approximately half of all B-PLL patients, indicating a potential role of MYC in this disease (Flatley et al, 2014) .
Multiple Myeloma (MM) is a mature B-cell disorder characterized by proliferation of plasma cell clones secreting monoclonal immunoglobulin. Based on the observation that MM frequently evolves slowly, often from a subclinical precursor clone producing monoclonal immunoglobulin, multiple mutations and complex chromosomal aberrations accumulate over years. Activation of CCND1 is considered an early event in the pathogenesis of MM with MYC overexpression following at a later time point (Shou et al, 2000) . In murine models, MYC activation, directly by overexpression or indirectly via IL6-JAK-STAT3 signalling or activationinduced-deaminase (AID) during somatic hypermutation, leads to plasma cell disorders resembling human MM (Chesi et al, 2008; Dechow et al, 2014) . Recently, oncogenic MUC1 was identified to upregulate MYC in MM through b-catenin/ TCF4 (Tagde et al, 2016) and interferon regulator 4 (IRF4). IRF4, which is essential for MM survival, is also known to target MYC (Shaffer et al, 2008) . Moreover, several chromosomal aberrations involving and activating the MYC locus have been linked to adverse prognosis and more aggressive phenotype (Shou et al, 2000; Avet-Loiseau et al, 2001) .
In a subgroup of patients with Hodgkin lymphoma (HL), Reed-Sternberg cells are characterised by a gene signature enriched for MYC target genes with a great degree of overlap with known NOTCH1 and IRF4 targets, which indicates that MYC might play a role in this lymphoma subtype too (Tiacci et al, 2012) .
T-cell malignancies
In normal T-cell physiology, MYC is essential for T-cell development and differentiation (Douglas et al, 2001) , for orchestrating metabolic events to enable rapid T-cell proliferation upon activation (Wang et al, 2011) , and for sustaining proper function of CD8 + T-cells after priming (Chou et al, 2014) . MYC expression and turnover is however tightly regulated to fulfil its purposes in the right context. Anaplastic large cell lymphoma (ALCL) is an aggressive T-cell neoplasm characterised by fusion of NPM1 and the Anaplastic lymphoma kinase (ALK) gene via translocation t(2;5)(p23;q35), and by expression of CD30. MYC rearrangements have been described in paediatric ALCL patients and were associated with adverse prognosis (Liang et al, 2013) . IRF4 has been shown to regulate MYC activation and, therefore, impair survival in ALCL cells (Weilemann et al, 2015) . Other factors contributing to MYC activation in ALCL include WNT/b-catenin and JAK-STAT signalling (Zhang et al, 1996; Wu et al, 2016) .
MYC also plays a key role in T-cell acute lymphoblastic leukaemia (T-ALL), in which it is activated via two independent mechanisms: Firstly, activating NOTCH1 mutations, present in 60% of T-ALLs, lead to increased MYC expression (Weng et al, 2004) . Secondly, MYC translocations have been found in in 6% of T-ALLs resulting in direct activation of MYC (La Starza et al, 2014) . Preclinical evidence indicates that enforced Myc expression leads to a T-ALL-like disease in zebrafish (Langenau et al, 2003) , and that MYC is necessary for T-ALL initiation and maintenance in mice (Roderick et al, 2014). These experimental data further emphasize the role of MYC in T-ALL. T-prolymphocytic leukaemia (T-PLL) is rare disorder caused by clonal expansion of post-thymic T-cells, commonly involving spleen, lymph nodes, bone marrow and peripheral blood. Apart from chromosomal alterations involving TCL1A (also termed TCL1), MTCP1 and the T-cell receptor, MYC gains can also be found in T-PLL (Tirado et al, 2012; Hsi et al, 2014) . The exact role and prognostic implications of these signalling pathways in the pathogenesis of T-PLL remain elusive.
Myeloid malignancies
The fact that MYC plays a role in acute myeloid leukaemia (AML), a highly aggressive and hard to treat malignant neoplasm originating from haematopoietic stem cells or myeloid progenitors, has been known for decades. Early studies proposed MYC amplifications and increased MYC RNA in AML (Alitalo et al, 1985) . Evidence from murine bone marrow transduction/transplantation models shows that enforced MYC expression without further anti-apoptotic hits exclusively induces a phenotype resembling AML (Luo et al, 2005) and that this phenotype originates from increased apoptotic resistance due to increased myeloid leukaemia cell differentiation protein (MCL1) expression in myeloid progenitors (Xiang et al, 2010) . Recently, efforts to provide further insights into the pathogenesis and prognosis of AML by performing next generation sequencing in a large number of patients enrolled in clinical trials revealed novel hot-spot mutations in MYC, further emphasizing its role in AML (Papaemmanuil et al, 2016) . The fusion genes RUNX1-RUNX1T1 (AML1-ETO), PML-RARA and ZBTB16 (PLZF)-RARA have also been shown to induce WNT-signalling, thereby indirectly increasing MYC levels (Muller-Tidow et al, 2004) . In FLT3-internal tandem duplication AML, which is associated with treatment resistance and adverse prognosis, MYC mediates the protection of leukaemic stem cells from FLT3 tyrosine kinase inhibitors via indirect stabilization of the histone deacetylase SIRT1 .
Chronic myeloid leukaemia (CML) arises from a transformed haematopoietic stem cell caused by the BCR/ABL1 translocation. ABL kinase inhibitors (imatinib, dasatinib, nilotinib) have revolutionised the treatment of CML, but in most cases the leukaemia-initiating cell/leukaemia stem cells (LIC/LSC) compartment cannot be fully eradicated. MYC has been implicated in resistance to BCR-ABL1 inhibitors by blocking differentiation (Gomez-Casares et al, 2013) , and increased MYC levels are associated with adverse prognosis (Albajar et al, 2011) . MYC ubiquitination by the ubiquitin ligase FBXW7 regulates CML LSC/LIC survival and FBXW7 is required for maintenance of human CML (Reavie et al, 2013) . By using a systems biology approach Abraham et al (2016) were able to overcome the problem of imatinib-resistant LSC by perturbation of both TP53 and MYC activity, and not BCL-ABL1 itself, which resulted in synergistic cell kill, differentiation, and near elimination of transplantable human LSCs in mice, while sparing normal haematopoietic stem cells.
Strategies to target MYC-related cancer cell biology and specific liabilities
Given the fundamental role of MYC in the initiation and progression in the aforementioned haematological malignancies (overview in Table I ) and its frequent association with aggressive clinical course, treatment resistance and adverse prognosis, the idea of targeting MYC is enticing. As expected from a transcription factor that regulates elongation in a more or less dose-dependent manner (Wolf et al, 2015) , MYC's involvement in biological processes is multifaceted. Potential therapeutic strategies are diverse and involve direct and indirect MYC targeting, both of which will be discussed here (Fig 1) . 
Direct MYC targeting
MYC is crucially involved in normal cellular, tissue and organism homeostasis (Eilers & Eisenman, 2008; Meyer & Penn, 2008) . Consequently, whether potent MYC inhibition will have a therapeutic window, as suggested by the aforementioned OmoMyc mouse model, is a central question. Small molecule inhibitors used in cancer therapy often target the active sites of proteins exhibiting enzymatic activities. As MYC lacks hydrophobic pockets and its structure makes it difficult to directly target the MYC protein, the majority of direct inhibitors aim to interfere with the MYC-MAX interaction.
Multiple small molecules target the MYC-MAX interaction and hence affect MYC-dependent transcription. The most studied molecule is 10058-F4, which shows anti-tumour effects in various established cancer cell lines (Yin et al, 2003; Huang et al, 2006) . 10058-F4 has heretofore not shown to be effective in in vivo settings due to poor bioavailability and rapid metabolism (Whitfield et al, 2017) . Other inhibitors include pyrimidine-and pyridine-based compounds (Kiessling et al, 2007; Hart et al, 2014 ) that also inhibit MYC-MAX and show activity in vivo (Stellas et al, 2014) . Nevertheless, no small molecule inhibitor targeting MYC is in clinical trials at this time.
Another possible means for targeting the addiction of cancer cells to elevated MYC levels is to reduce MYC stability by enforced degradation. MYC stability and its proteasomal degradation is tightly regulated and frequently impaired in haematological malignancies (reviewed in (Farrell & Sears, 2014) . KITLG (SCF) Fbw7 is the best-studied E3 ubiquitin ligase involved in the regulation of MYC protein turnover, where Fbw7 represents the F-box substrate specificity component. The underlying mechanism is dependent on MYC phosphorylation and triggers proteasomal degradation of MYC upon its ubiquitination (Welcker et al, 2004) . Mutations and subsequent changes in the phosphorylation of MYC are found in various types of haematological disorders. These changes inhibit Fwb7-mediated degradation and stabilise MYC protein (Bahram et al, 2000) . These data indicate that targeting the pathways involved in MYC phosphorylation and degradation represents a promising therapeutic approach for cancers addicted to high MYC levels. The ubiquitin-dependent degradation of MYC is antagonised by the deubiquitinase USP28. High levels of USP28 increase the stability of MYC protein and are present in different types of cancers, which is essential for sustaining tumour cell proliferation (Popov et al, 2007) . Moreover, studies in a model of colorectal cancer showed that USP28 is induced by MYC and that inhibition of USP28 inhibits growth of tumour cells (Diefenbacher et al, 2014) . However, whether or not this will be relevant in haematological malignancies will require further research.
Indirect MYC targeting
The adversities of directly targeting MYC have led to exploiting MYC-associated and MYC-dependent pathways as therapeutic targets. The rationale of this concept, termed synthetic lethality, is to identify and target pathways or mutations that are present in tumour cells but not in normal cells (Guarente, 1993; Kaelin, 2005) . In the context of activated MYC, targeting a gene product that is synthetic lethal should kill only cancer cells and spare normal cells. In other words, MYC synthetic lethal interventions take advantage of a specific MYC-mediated vulnerability, e.g. by pharmacologically inhibiting an enzyme or a protein interaction. However, there are also other approaches to target MYC activation that do not fulfil these criteria. In the following sections we discuss how such MYC addiction or MYC-related vulnerabilities could be exploited in novel cancer therapies (Fig 1) .
Epigenetic dysregulation. Aberrant gene expression patterns occur in a broad spectrum of haematological malignancies. These patterns are heavily influenced by epigenetic dysregulation, such as DNA methylation, histone modifications and chromatin remodelling (Delmore et al, 2011) . MYC acts as a regulator of these processes on various levels and recruits DNA methyltransferases (DNMTs) to promoter regions of non-canonical target genes to suppress gene expression. Moreover, MYC regulates polycomb proteins and is thereby remodelling chromatin structures [reviewed in (Poole & van Riggelen, 2017) ]. Here we will focus on inhibition of histone deacetylases (HDACs) and bromodomain and extra-terminal motifs (BETs), because drugs targeting histone modifiers and effectors are best characterized in the context of MYC activation. The acetylation of histone tails is controlled by two adversely active families of enzymes, HATs and HDACs. HATs catalyse the acetylation of histone tails and enhance gene expression by altering the DNA-histone interaction. Conversely, HDACs reverse lysine acetylation and repress transcription (Bannister & Kouzarides, 2011) . HDACs are part of MYC-induced gene repression (see above). They are recruited to protein-coding genes by MYC and mediate their deacetylation. As a consequence, the local chromatin structure is stabilized and gene expression is repressed (Kurland & Tansey, 2008) . Inhibition of HDACs suppresses MYC (Gui et al, 2004; Bhadury et al, 2014) and/or disturbs the transcriptional MYC signature. Multiple mechanisms lead to the clinical activity of HDAC inhibition, among them altered expression of cell-cycle proteins, apoptotic proteins and DNMTs (Schrump, 2009; Lemoine & Younes, 2010; Harada et al, 2017) . At this time, several HDAC inhibitors are part of clinical studies and are used for the clinical management of haematological disorders, which are at least partly MYCdriven (Olsen et al, 2007; Piekarz et al, 2009; Whittaker et al, 2010) . However, further studies need to establish the clinical usefulness of such HDAC inhibitors based on evaluation of the MYC status. Furthermore, HDAC inhibitors are also differentially selective where pan-HDAC inhibitors such as panobinostat, which is approved for MM, potentially also In transcriptional regulation, acetylation motifs are recognized by BET proteins. BET proteins function as epigenetic readers and recognize acetylated histone proteins within chromatin and modify gene transcription by recruiting transcriptional regulators. Importantly, in some contexts BET proteins are direct regulators of MYC expression, and inhibition of BETs raised attention because it suppressed MYC expression and showed therapeutic efficacy in a preclinical model of KMT2A (MLL)-driven leukaemia and MM (Filippakopoulos et al, 2010; Delmore et al, 2011) . B-cell lymphomas from genetically-engineered mouse models were also sensitive to BET inhibitors (BETi), but not via suppression of MYC (Bhadury et al, 2014; Donato et al, 2017) . This suggests that the chromatin environment dictates if MYC will be regulated by BET or not. However, given that BET proteins would also bind acetylated histones stimulated by MYCmediated recruitment of HATs, MYC and BET proteins are probably linked irrespective of whether it is upstream or downstream (Wolf et al, 2015; Donato et al, 2017) . With the emergence of more potent compounds based on PROTACtechnologies (Winter et al, 2015; Zengerle et al, 2015) , BETi may find their way into the clinic.
Cell cycle and DNA damage response. One of the major biological effects of MYC activation is enhanced cell proliferation. MYC accelerates the G1 and S phase transition by induction of various components of the cell cycle machinery and concomitant suppression of negative regulators. Fittingly, several of these positive regulators of G1-S transition (e.g. E2F1, CDK4) harbour high-affinity binding sites and were previously termed 'direct' MYC target genes [reviewed in (Amati et al, 1998; Bretones et al, 2015) ]. In addition, one main characteristic of MYC-driven malignancies is the suppression of the cyclin-dependent kinase inhibitor CDKN1B (p27 Kip1 , p27), both directly by MYC suppression of CDKN1B transcription, and, probably even more effective, the enforced degradation of CDKN1B protein by means of the KITLG Skp2/Cks1 ubiquitin ligase (Slingerland & Pagano, 2000) . SKP2 and CKS1, both required for adequate CDKN1B recognition by the E3 KITLG-type ligase, are induced by MYC and overexpressed in MYC-driven lymphoma (Keller et al, 2007; Old et al, 2010) . Despite these promising connections, mouse models do not support that targeting the CDKN1B degradation axis or CDK4, for which there is a recent US Food and Drug Administration-approved inhibitor (Palbociclib; Clark et al, 2016) will cause an effect on MYCdriven blood malignancies. Deletion of Cdk4 in El-Myc mice does not impair and may even accelerate lymphomagenesis and Skp2 deletion resulted in CDKN1B accumulation to the same level as Cks1b (Cks1) deletion but did not result in a delay in lymphomagenesis, at variance with Cks1b deletion (Keller et al, 2007; Old et al, 2010) . CDK4/ CDK6 inhibition could however be of interest in highly proliferative MCL (Leonard et al, 2012) , because these overexpress CCND1. Whether or not concomitant MYC translocations render them more sensitive or rather resistant remains to be assessed. Synthetic lethality approaches may be of particular potential when targeting the G2 checkpoint and mitosis, where MYC seems to create particular vulnerabilities (Bretones et al, 2015; Sherr & Bartek, 2017) . Inhibition of CDK1 was particularly effective in cancer cells with activated MYC and induced cell death in MYC-driven lymphoma cells (Goga et al, 2007) . Beside CDKs, the mitosis regulators Aurora kinases A and B are attractive targets in MYC-driven cancers. They regulate mitotic spindle assembly and gene amplifications are found in a variety of human cancers. The transcript and protein levels are highly elevated in human MYC-driven B cell lymphomas and blocking of kinase activity with selective inhibitors impairs mitosis and triggers apoptosis (den Hollander et al, 2010) .
MYC overexpression can result in DNA damage or DNA damage response signalling (Campaner & Amati, 2012) . Checkpoint kinase 1 (CHEK1) is a kinase involved in erroneous replication, which can be caused by nucleotide depletion, UV radiation or excess transcriptional initiation e.g. by MYC overexpression (Campaner & Amati, 2012) . High MYC levels correlate with high CHEK1 levels in B-cell lymphomas and CHEK1 inhibition results in apoptosis in models of B-cell lymphoma (Hoglund et al, 2011) (Murga et al, 2011) . CHEK1 inhibitors have been developed and are continuously being improved (Hoglund et al, 2011; Horiuchi et al, 2014) but, as of yet, no inhibitor has been tested in a phase 3 clinical trial.
The exact mechanisms of the synthetic lethality interactions between MYC and CDK1/AURKB/CHEK1 is not known but could involve a failure of MYC overexpressing cells to arrest in the cell cycle and their fast proliferation, or that the aberrant and elevated transcription could result in production or loss of gene products that are detrimental or essential to cells blocked in mitosis, respectively. Potential candidates are anti-apoptotic members of the BCL2 family since one of them, MCL1, is degraded in mitosis resulting in cells depending on e.g. BCL2 and BCL2L1 (Bcl-XL) .
Re-establishing apoptosis. Induction of apoptosis by high MYC levels is a crucial safeguard mechanism preventing rampant proliferation and cancer development (Nilsson & Cleveland, 2003) . Accordingly, TP53 deficiency or concurrent overexpression of BCL2 can overcome MYC-induced apoptosis and lead to treatment resistance, as seen in DHL/DEL (Johnson et al, 2012) . Therefore, the clinically approved BH3-mimetic/BCL2 inhibitor ABT199 is a potential candidate to combat treatment resistance in DHL/DEL (Cinar et al, 2015) . Induced MCL1 represents another promising target for leukaemia/lymphoma, because haplo-insufficiency of MCL1 remarkably slows or prevents development of MYC-driven cancer in murine leukaemia and lymphoma models (Xiang et al, 2010; Kelly et al, 2014) . Recent work showing that a novel MCL1 inhibitor is effective in preclinical myeloma, lymphoma and leukaemia models further supports the potential of this approach (Kotschy et al, 2016) . Due to the collaboration of MCL1 and BCL2, which can compensate for each other in DLBCL, dual inhibition of MCL1 and BCL2 with dinaciclib, an inhibitor of CDK9 resulting in MCL1 reduction, and ABT199, is highly synergistic in preclinical models of DHL (Li et al, 2015) . In healthy tissue, MYC induces CDKN2A (Arf), which inhibits mouse double minute 2 homolog (MDM2), an E3 ubiquitin ligase that targets TP53 to degradation. In lymphoma, CDKN2A is frequently mutated resulting in reduced TP53 levels. Restoring or increasing lost TP53 activity can be achieved by inhibiting MDM2 with nutlin-3, which was effective in CLL, AML and MM without TP53 mutations (Kojima et al, 2005; Stuhmer et al, 2005; Secchiero et al, 2006) . Clinical trials with novel MDM2 inhibitors are currently being conducted. In summary, re-establishing functional apoptotic pathways by means of pharmacologically restoring a cancer "primed for death program" could be of particular interest in MYCaddicted malignancies.
Protein biosynthesis. MYC triggers protein biosynthesis by increasing the expression of housekeeping genes, including factors comprising the translation machinery, thereby operating the massive demand of cancer cell proliferation and growth. Ribosomal biogenesis, translation initiation factors and RNA polymerase, among other key aspects of protein biosynthesis, are directly regulated by MYC (van Riggelen et al, 2010) . Also, inhibitions of translation initiation and RNA polymerase have been shown to directly affect MYC expression (Lee et al, 2017; Manier et al, 2017) . The phosphoinositide-3-kinase (PI3K)-mammalian/mechanistic target of rapamycin (MTOR) axis, including its downstream effector initiation factor of translation (EIF4E), is known to be an essential regulator of translation and strongly cooperates with MYC (Ruggero et al, 2004; Sander et al, 2012) . This axis can be targeted by clinically approved inhibitors of MTOR (everolimus) and PI3K (idelalisib), conferring synthetic lethality in cells with aberrant MYC expression (Pourdehnad et al, 2013) . Next to applying a combination of such inhibitors to abrogate compensatory feedback loops in this signalling pathway (Shortt et al, 2013) , dual MTOR/PI3K inhibitors may be particularly effective in cancers with elevated MYC. Another novel strategy to further enhance efficacy of PI3K-MTOR inhibitors was recently demonstrated by Devlin et al (2016) , who utilized a novel inhibitor of rDNA transcription to additionally target ribosomal biogenesis. This resulted in remarkable preclinical efficacy and synergistic activity with everolimus in MYC-driven lymphoma (Devlin et al, 2016) . Given the manageable side-effect profile of PI3K-MTOR signalling inhibitors, clinical trials investigating these agents specifically in the context of MYC-depending malignancies are highly warranted.
Post-translational protein modification (PTM). PTMs modulate protein function and abundance, with pivotal roles in basically all cellular processes. The ubiquitin proteasome system (UPS) is the central cellular degradation machinery which controls the levels and quality of many regulatory proteins through a process containing a cascade of enzymes [reviewed in (Hochstrasser, 2009) ]. Protein quality control is a key necessity in MYC-driven cancer cells because MYC enhances cellular growth and protein biosynthesis (van Riggelen et al, 2010) and targeting those sensitive pathways with e.g. proteasome inhibitors, such as bortezomib, is effective in frequently MYC-high disorders like MM by triggering endoplasmic reticulum stress (Crawford et al, 2008) . Treatment outcome using ixazomib, another proteasome inhibitor, was associated with MYC status of MM patients (Di Bacco et al, 2016) . Mechanistically, proteasome inhibition in MYCdriven lymphoma cells inhibits cell growth in part by lowering MYC expression (Suk et al, 2015) , which may explain the sensitivity of MYC-driven cancers to proteasome inhibition (see direct MYC targeting).
Similar to ubiquitylation, SUMOylation is carried out by an cascade involving E1, E2 and E3 enzymes [reviewed in (Creton & Jentsch, 2010) ]. Importantly, the SUMO conjugation pathway is highly abundant and active in MYC expressing cells. Inhibition of the E1 or E2 enzymes by pharmacological or genetic means kills MYC-driven cancer cells in a highly specific manner (Hoellein et al, 2014) . Such synthetic lethal interactions have also been shown in MYCdriven breast cancer (Kessler et al, 2012) . However, no clinical grade SUMOylation inhibitor is currently available.
Metabolism. In comparison to their healthy counterparts, rapidly dividing cancer cells have unique metabolic features and a high demand for nutrients. The 'Warburg effect' is a metabolic adaption representing a shift to increased aerobic glycolysis so that glucose can be used in anabolic processes via shunting of metabolites to the pentose phosphate pathway. Despite this, a substantial amount of lactic acid is still being produced and glutamine is even needed to provide metabolites for ATP production (Pavlova & Thompson, 2016) . There exists a correlation between high rates of glycolysis and treatment resistance, providing a rationale for targeting of glycolysis to halt tumour progression or to enhance treatment response (Maschek et al, 2004; Dorr et al, 2013) . This concept has been proposed earlier but has not yet demonstrated any usability in the clinic.
Most metabolic genes are housekeeping genes; they have an open chromatin state and their transcriptional elongation is therefore also enhanced by MYC (Sabo et al, 2014) . Many metabolic genes harbour high-affinity E-boxes and are therefore part of a 'MYC core' program (Dang, 2013; Li & Simon, 2013) . However, just because a gene is induced when MYC Review ª 2017 John Wiley & Sons Ltd levels are high does not make the gene essential for tumourigenesis, as has been revealed in mouse models of lymphoma (Nilsson et al, 2012) . Nevertheless, some genes have been studied in detail, including Glucose transporter 1 (SLC2A1) (Osthus et al, 2000) , glutamine synthase (GLUL) (Yuneva et al, 2007; Raez et al, 2013; Altman et al, 2016) , and lactate dehydrogenase (LDHA) (Shim et al, 1997) . Inhibition of LDHA with a small-molecule inhibitor (FX11) was effective in B-cell lymphoma (Le et al, 2010) . FX11 is a gossypol analogue that also may inhibit BCL2 and genetic inactivation of Ldha did not block lymphomagenesis (Nilsson et al, 2012) . Recently, a role of LDHA in immune evasion has also been described (Brand et al, 2016) . This effect could be a highly important consequence of the Warburg effect, and can now be investigated with more potent lactate dehydrogenase inhibitors being developed for clinical use (Boudreau et al, 2016) .
If lactate production is dispensable for lymphoma it may instead cause vulnerability. Intracellular accumulation of lactate is counteracted by the lactate exporter SLC16A1 (MCT1. Inhibition of SLC16A1 triggers cell death in MYC-driven lymphoma. Interestingly, Metformin, a compound disabling oxidative phosphorylation of pyruvate and forcing glycolysis, amplifies the effects of SLC16A1 inhibition and suggests a combination therapy for MYC-high haematological cancers (Doherty et al, 2014) . Whether or not the effect is due to cell intrinsic effects of lactate (toxicity) or due to a lack of lactate in the tumour microenvironment (immune suppression) remains to be studied (Boudreau et al, 2016; Brand et al, 2016) .
One of the first described MYC 'target genes' was ornithine decarboxylase (ODC now termed ODC1), encoding the first and the rate-limiting enzyme of polyamine biosynthesis (Bello-Fernandez et al, 1993) . Polyamines are organic cations that are derived from amino acids, are found in all organisms and are frequently dysregulated in cancer and other hyperproliferative diseases. Thus polyamine function and metabolism are attractive targets for therapeutic intervention with highly selective inhibitors already available in the 1970's (Gerner & Meyskens, 2004; Casero & Marton, 2007) . Given that the polyamine biosynthetic pathway is ubiquitous, not only ODC1 but also AMD1 (S-adenosylmethionone decarboxylase) and SRM (spermidine synthase), are housekeeping genes which have several high-affinity E-boxes in their genes that are bound by even slightly elevated levels of MYC (Nilsson et al, 2005) . The ODC1 inhibitor difluoromethylornithine (DFMO) was tested in MYCinduced lymphoma mouse models (Nilsson et al, 2005) . Whereas lymphoma development could be dramatically delayed by DFMO or the SRM inhibitor 4MCHA (Forshell et al, 2010) , DFMO or 4MCHA were not effective once lymphoma had developed. The mechanism is unlikely to involve a simple linear relation between MYC and ODC1 but rather a complex interplay between tumour cells and immune or stroma cells within the tumour microenvironment.
Immune response and immune checkpoint (de-)regulation. Tumour cells are frequently edited to bypass immune surveillance (Casey et al, 2014 (Casey et al, , 2017 . This occurs either through creating an immunosuppressive environment or by preventing recognition by immune cells (Casey et al, 2014) . Importantly, CD47 and CD274 (previously termed Programmed death-ligand 1, PD-L1), two immune checkpoint proteins expressed on the surface of tumour cells, are directly controlling the antitumour immune response by inhibiting activated T-cells (Casey et al, 2016) . High MYC levels results in elevated transcription of these genes in some tumour models. Besides immune checkpoint receptors, MYC has been shown to regulate many secreted, immune-associated molecules including type 1 interferon, and could alter the immune phenotype of cancer cells through multiple mechanisms (Schlee et al, 2007) . Taken together, it is possible that a subset of cancers expressing high levels of MYC may be particularly sensitive to immunotherapy. Agents such as nivolumab and pembrolizumab have proven strong efficacy in solid tumours (Galanina et al, 2017) and targeted immune checkpoint blockade is currently evaluated in various haematological cancers, albeit not in a manner that would allow deducting to the MYC status (Alatrash et al, 2016) .
In addition to the regulation of tumour cell-specific immune features, MYC maintains the tumour viability in a hostile tumour microenvironment. MYC inactivation in conditional transgenic mouse models showed that CD47 and CD274 is suppressed and that this is crucial for the recruitment of T-cells and macrophages modifying the tumour microenvironment. This and massive changes in cytokine signalling leads to tumour regression after MYC inactivation and triggers an anti-tumour immune response (Rakhra et al, 2010; Casey et al, 2016) . Therapeutic targeting of MYC-associated pathways could thus be effective to restore the host immune system (Casey et al, 2017) . Notably, MYC is however also very important for T cell proliferation (Wang et al, 2011) .
Conclusions
The previously complex biology of MYC has recently been simplified with the understanding that MYC acts as the grease in the machinery of cancer cells. By altering the expression of numerous cancer-promoting genes, MYC at the same time creates vulnerabilities. Future preclinical and clinical studies will have to assess whether MYC should rather be targeted directly or whether or not the vulnerabilities created by the broad transcriptional effects can be exploited for cancer therapy. 
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